COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic
Authors:
- Mathias CastonguayMathias Castonguay
- Nawar DakhallahNDNawar Dakhallah
- Justin DesrochesJustin Desroches
- Marie-Laure ColaiacovoMCMarie-Laure Colaiacovo
- Camille Jimenez-CortesCJCamille Jimenez-Cortes
- Anne-Marie ClaveauACAnne-Marie Claveau
- Samuel BérubéSBSamuel Bérubé
- Amer Yassine HafsaouiAHAmer Yassine Hafsaoui
- Amalia SouzaASAmalia Souza
- Pauline TiboutPTPauline Tibout
- Christophe Ah-YanCAChristophe Ah-Yan
- Anne-Marie VincentAVAnne-Marie Vincent
Open Access
- 12 December 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (24) , 7361
Abstract
Background: Patients with sickle cell disease (SCD) are considered at higher risk of severe COVID-19 infection. However, morbidity and mortality rates are variable among countries. To date, there are no published reports that document outcomes of SCD patients with COVID-19 in Canada. Methods: A web-based registry was implemented in June 2020 capturing outcomes of SCD patients with COVID-19 from March 2020 to April 2022 and comparing them to the general population of Quebec, Canada. Results: After 24 months of the pandemic, 185 SCD patients with confirmed SARS-CoV-2 infection were included in the registry. Overall, the population was young (median age 12 years old) and had few comorbidities. No deaths were reported. Risk of hospitalization and admission to intensive care unit (ICU) because of COVID-19 was higher in patients with SCD than in the general population (relative risks (RR) 5.15 (95% confidence interval (95% CI) 3.84–6.91), p ˂ 0.001 and 4.56 (95% CI 2.09–9.93) p ˂ 0.001). A history of arterial hypertension or acute chest syndrome in the past 12 months was associated with a higher risk of severe disease (RR = 3.06 (95% CI 1.85–5.06) p = 0.008 and 2.27 (95% CI 1.35–3.83) p = 0.01). Hospitalized patients had lower hemoglobin F than non-hospitalized patients (12% vs. 17%, p = 0.02). For those who had access to vaccination at the time of infection, 25 out of 26 patients were adequately vaccinated and had mild disease. Conclusions: The SCD population is at higher risk of severe disease than the general population. However, we report favorable outcomes as no deaths occurred. Registries will continue to be critical to document the impact of novel COVID-19 specific therapy and vaccines for the SCD population.Keywords
This publication has 20 references indexed in Scilit:
- Coronavirus Disease among Persons with Sickle Cell Disease, United States, March 20–May 21, 2020Emerging Infectious Diseases, 2020
- Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inactionBMJ, 2020
- Role of the coagulation system in the pathogenesis of sickle cell diseaseBlood Advances, 2019
- Sickle cell disease: a review for the internistInternal and Emergency Medicine, 2019
- Fetal hemoglobin in sickle cell anemiaBlood, 2011
- Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell diseaseBlood, 2010
- Pandemic influenza A (H1N1) virus infections in children with sickle cell diseaseBlood, 2010
- Definitions of the phenotypic manifestations of sickle cell diseaseAmerican Journal of Hematology, 2009
- Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell DiseaseNew England Journal of Medicine, 2000
- Causes of death in sickle-cell disease in Jamaica.BMJ, 1982